慢性淋巴细胞白血病中从头染色质激活的双重生物学作用及其临床影响
本研究探讨慢性淋巴细胞白血病(CLL)中从头染色质激活水平与临床行为的关系,发现部分调控区域的染色质激活增加与临床进展相关,而另一些区域则与惰性病程相关。研究者据此构建了分别针对进展性和惰性疾病的两个预后评分,并计算代表二者平衡的单一评分及基于靶基因和蛋白表达的替代评分。该平衡评分在独立CLL队列及染色质、转录组或蛋白质组数据中,被验证为首次治疗时间的强效且独立定量预后因素。
要点
- 部分调控区域的从头染色质激活增加与CLL临床进展相关,另一些区域则与惰性病程相关。
- 基于进展性和惰性分别构建的两个预后评分,其平衡评分优于任一单独评分。
- 平衡评分在独立CLL队列及多种数据模态中,被验证为首次治疗时间的强效且独立定量预后因素。
核心结论
- CLL细胞中从头获得的染色质变化具有双重生物学作用,促进展与促惰性之间的平衡是CLL预后的强效独立决定因素。
研究设计与样本
- 本研究比较CLL与正常B细胞的从头染色质激活模式,分析染色质激活水平与CLL临床行为的关系,并构建预后评分。
- 研究开发了分别针对进展性疾病和惰性疾病的2个预后评分,计算代表二者平衡的单一评分,并基于靶基因和蛋白表达生成替代评分。
- 研究在独立CLL队列及染色质、转录组或蛋白质组数据模态中验证平衡评分。
主要发现
- 部分调控区域的从头染色质激活增加与临床进展相关,而其他区域的增加与惰性病程相关。
- 平衡评分优于2个单独评分的临床影响,似乎捕捉了每个单独评分提供的预后信息。
- 平衡评分较高的CLL显示肿瘤坏死因子α(TNF-α)/NF-κB和mTOR信号通路激活增加。
- 与进展相关的调控程序主要在淋巴结微环境中激活,而与惰性疾病相关的调控程序似乎不依赖微环境。
- 平衡评分在独立CLL队列及染色质、转录组或蛋白质组数据中,被验证为首次治疗时间的强效且独立定量预后因素。
关键数值与推荐
- 原文未报告具体的评分阈值、风险比、置信区间或P值。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Previous studies have reported that chronic lymphocytic leukemia (CLL) shows a de novo chromatin activation pattern compared with normal B cells. Here, we explored whether the level of chromatin activation is related to the clinical behavior of CLL. We identified that, in some regulatory regions, increased de novo chromatin activation is linked to clinical progression, whereas, in other regions, it is associated with an indolent course. We next developed 2 prognostic scores for progressive and indolent disease, respectively, calculated a single score representing the balance between them, and further generated surrogate scores based on gene and protein expression of the target genes. The balance score outperformed the clinical impact of the 2 individual scores, because it seemed to capture the prognostic information provided by each of them. Biologically, CLLs with higher balance score showed increased activation of tumor necrosis factor alpha (TNF-α)/NF-κB and mTOR signaling pathways. Regulatory programs related to progression were predominantly activated in the lymph node microenvironment, whereas those linked to indolent disease appeared to be microenvironment independent. Finally, we thoroughly validated the balance score as a powerful and independent quantitative prognostic factor for time to first treatment across independent CLL cohorts and data modalities, such as chromatin, transcriptome, or proteome data. Our findings support the concept that de novo acquisition of chromatin changes in CLL cells plays a dual biological role, and the balance between proprogression and proindolence is a strong independent determinant of CLL prognosis.
引用
- Chapaprieta V, Maiques-Diaz A, Nadeu F, et al. Dual biological role and clinical impact of de novo chromatin activation in chronic lymphocytic leukemia. Blood. 2025. PMID: 39841466. doi:10.1182/blood.2024025396
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。